Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician-diagnosed peanut allergy OR convincing clinical history of peanut allergy~* Reacts to a cumulative dose of 2,000 mg or less of peanut powder~* Positive peanut allergy skin prick test OR detectable serum peanut-specific IgE level~* Willing to use an acceptable method of contraception for the duration of the study~* Ability to perform spirometry maneuver in accordance with the American Thoracic Society guidelines~Exclusion Criteria:~* History of severe anaphylaxis to peanut~* Currently participating in a study using a new investigational new drug~* Participation in any interventional study for the treatment of food allergy in the 12 months prior to study entry~* Allergic to placebo ingredients (glycerin or oat flour) OR reacts to any dose of placebo during study entry oral food challenge (OFC)~* Currently in a buildup phase of any allergy immunotherapy~* Poor control of atopic dermatitis~* Moderate or severe asthma despite therapy~* Current treatment with greater than medium daily doses of inhaled corticosteroids~* Use of steroid medications~* Use of omalizumab or other nontraditional forms of allergen immunomodulatory therapy (not including corticosteroids) or biologic therapy in the 12 months prior to study entry~* Use of beta blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or calcium channel blockers~* Inability to discontinue antihistamines for skin testing and OFCs~* History of ischemic cardiovascular disease~* History of alcohol or drug abuse~* Other significant medical conditions that, in the opinion of the investigator, prevent participation in the study~* Previous intubation due to allergies or asthma~* Uncontrolled high blood pressure~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Peanut SLIT (Double Blind to Open Label) (Type: EXPERIMENTAL): Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for \>= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume \>= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
- Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL) (Type: PLACEBO_COMPARATOR): Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for \>= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.

Based on this trial design, predict the completion outcome and termination type (if applicable).